NO20006178L - Anvendelse av PEG-IFN-<alfa> og ribavirin for behandling av kronisk hepatitt C - Google Patents

Anvendelse av PEG-IFN-<alfa> og ribavirin for behandling av kronisk hepatitt C

Info

Publication number
NO20006178L
NO20006178L NO20006178A NO20006178A NO20006178L NO 20006178 L NO20006178 L NO 20006178L NO 20006178 A NO20006178 A NO 20006178A NO 20006178 A NO20006178 A NO 20006178A NO 20006178 L NO20006178 L NO 20006178L
Authority
NO
Norway
Prior art keywords
ribavirin
ifn
peg
alpha
treatment
Prior art date
Application number
NO20006178A
Other languages
English (en)
Other versions
NO325598B1 (no
NO20006178D0 (no
Inventor
Friederike Zahm
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8232086&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20006178(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20006178L publication Critical patent/NO20006178L/no
Publication of NO20006178D0 publication Critical patent/NO20006178D0/no
Publication of NO325598B1 publication Critical patent/NO325598B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
NO20006178A 1998-06-08 2000-12-05 Anvendelse av PEG-IFN-<alfa>2A konjugat og ribavirin for fremstilling av et medikament for behandling av kronisk hepatitt C infeksjoner og PEG-IFN-<alfa>2A konjugater sammen med ribavirin for anvendelse i terapi. NO325598B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98110433 1998-06-08
PCT/EP1999/003746 WO1999064016A1 (en) 1998-06-08 1999-05-29 Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c

Publications (3)

Publication Number Publication Date
NO20006178L true NO20006178L (no) 2000-12-05
NO20006178D0 NO20006178D0 (no) 2000-12-05
NO325598B1 NO325598B1 (no) 2008-06-23

Family

ID=8232086

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006178A NO325598B1 (no) 1998-06-08 2000-12-05 Anvendelse av PEG-IFN-<alfa>2A konjugat og ribavirin for fremstilling av et medikament for behandling av kronisk hepatitt C infeksjoner og PEG-IFN-<alfa>2A konjugater sammen med ribavirin for anvendelse i terapi.

Country Status (35)

Country Link
US (3) US20030053986A1 (no)
EP (1) EP1087778B1 (no)
JP (2) JP3839667B2 (no)
KR (2) KR20010052622A (no)
CN (1) CN1170543C (no)
AR (1) AR019855A1 (no)
AT (1) ATE307597T1 (no)
AU (1) AU767131B2 (no)
BR (1) BR9911076A (no)
CA (1) CA2334267C (no)
CL (1) CL2010000828A1 (no)
CO (1) CO5050297A1 (no)
CZ (1) CZ298681B6 (no)
DE (1) DE69927971T2 (no)
DK (1) DK1087778T3 (no)
ES (1) ES2251196T3 (no)
HK (1) HK1037981A1 (no)
HR (1) HRP20000808A2 (no)
HU (1) HU228218B1 (no)
ID (1) ID29285A (no)
IL (2) IL139786A0 (no)
MA (1) MA26641A1 (no)
MY (1) MY124091A (no)
NO (1) NO325598B1 (no)
NZ (1) NZ508249A (no)
PE (1) PE20000560A1 (no)
PL (1) PL192364B1 (no)
RS (1) RS50144B (no)
RU (1) RU2271217C2 (no)
SA (1) SA99200208B1 (no)
SI (1) SI1087778T1 (no)
TR (1) TR200003635T2 (no)
TW (1) TWI241913B (no)
WO (1) WO1999064016A1 (no)
ZA (1) ZA200006814B (no)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL192364B1 (pl) * 1998-06-08 2006-10-31 Hoffmann La Roche Zastosowanie koniugatu PEG-IFN-α 2A w połączeniu z rybawiryną
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
NZ547204A (en) 2000-05-26 2008-01-31 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
US7208167B2 (en) 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
DK1311279T3 (da) * 2000-08-07 2007-02-12 Sciclone Pharmaceuticals Inc Behandling af hepatitis C med thymosin, interferon og ribavirin
US7179791B2 (en) 2001-01-11 2007-02-20 Duke University Inhibiting GS-FDH to modulate NO bioactivity
KR100480429B1 (ko) * 2001-12-04 2005-04-06 선바이오(주) 인터페론-알파와 폴리에틸렌글리콜 유도체의 배합체
NZ537662A (en) * 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
WO2004002999A2 (en) 2002-06-28 2004-01-08 Idenix (Cayman) Limited Modified 2' and 3' -nucleoside produgs for treating flaviridae infections
AU2003248748A1 (en) * 2002-06-28 2004-01-19 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
KR20050088079A (ko) 2002-11-15 2005-09-01 이데닉스 (케이만) 리미티드 2'-분지형 뉴클레오시드 및 플라비비리다에 돌연변이
CA2509687C (en) * 2002-12-12 2012-08-14 Idenix (Cayman) Limited Process for the production of 2'-branched nucleosides
RU2005123395A (ru) * 2002-12-23 2006-01-27 Айденикс (Кайман) Лимитед (Ky) Способ получения 3-нуклеозидных пролекарств
CA2734052A1 (en) 2003-05-30 2005-01-13 Pharmasset, Inc. Modified fluorinated nucleoside analogues
CA2571675A1 (en) * 2004-06-23 2006-01-05 Idenix (Cayman) Limited 5-aza-7-deazapurine derivatives for treating infections with flaviviridae
US7857760B2 (en) 2004-07-13 2010-12-28 Dexcom, Inc. Analyte sensor
RU2433124C2 (ru) 2004-09-14 2011-11-10 Фармассет, Инк. Способ получения 2'-фтор-2'-алкилзамещенных или других замещенных рибофуранозилпиримидинов и пуринов и их производных
EP1814988A2 (en) 2004-11-26 2007-08-08 Pieris AG Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
EP1917037A2 (en) * 2005-08-15 2008-05-07 F.Hoffmann-La Roche Ag Peg-ifn alpha and ribavirin for hbv treatment
US9201979B2 (en) * 2005-09-14 2015-12-01 Millennial Media, Inc. Syndication of a behavioral profile associated with an availability condition using a monetization platform
JP5254033B2 (ja) * 2005-12-23 2013-08-07 イデニク プハルマセウティカルス，インコーポレイテッド 分岐型ヌクレオシドを調製するための合成中間体の製造方法
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
EP2313430B1 (en) 2008-06-24 2018-05-02 Technische Universität München Muteins of hngal and related proteins with affinity for a given target
JP5539363B2 (ja) * 2008-09-17 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング インターフェロンおよびリバビリンとのｈｃｖｎｓ３プロテアーゼ阻害剤の組合せ
CL2009002206A1 (es) 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
EA201100851A1 (ru) 2008-12-23 2012-04-30 Фармассет, Инк. Аналоги нуклеозидов
NZ593648A (en) 2008-12-23 2013-09-27 Gilead Pharmasset Llc Nucleoside phosphoramidates
EP2427213B1 (en) 2009-05-08 2015-04-01 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
JP2013501033A (ja) 2009-08-05 2013-01-10 ピエリス アーゲー リポカリン突然変異タンパク質の制御放出製剤
NZ598465A (en) 2009-10-30 2013-10-25 Boehringer Ingelheim Int Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
DK2510357T3 (en) 2009-12-07 2016-07-18 Pieris Ag MUTEINS OF HUMAN LIPOCALIN 2 (LCN2, HNGAL) WITH AFFINITY FOR A SPECIFIC TARGET
BR112012024884A2 (pt) 2010-03-31 2016-10-18 Gilead Pharmasset Llc síntese estereosseletiva de ativos contendo fósforo
WO2011154420A2 (en) 2010-06-08 2011-12-15 Pieris Ag Tear lipocalin muteins binding il-4 r alpha
KR20180088745A (ko) 2010-08-16 2018-08-06 피어이스 파마슈티컬즈 게엠베하 헵시딘 결합 단백질
AU2011331232B2 (en) 2010-11-15 2015-05-07 Pieris Ag Muteins of human lipocalin 2 with affinity for Glypican-3 (GPC3)
AR084044A1 (es) 2010-11-30 2013-04-17 Pharmasset Inc Compuestos 2’-espiro-nucleosidos
US9221885B2 (en) 2010-12-02 2015-12-29 Pieris Ag Muteins of human lipocalin 2 with affinity for CTLA-4
CN104244945B (zh) 2011-09-16 2016-08-31 吉利德制药有限责任公司 用于治疗hcv的方法
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
CA2858962C (en) 2011-12-13 2023-09-05 Pieris Ag Compositions of human tear lipocalin muteins and methods of use thereof
US9522940B2 (en) 2012-05-23 2016-12-20 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3
US20140039923A1 (en) * 2012-08-03 2014-02-06 AxelaCare Health Solutions, Inc. Computer program, method, and system for receiving and managing patient data gathered during patient treatments
WO2014076321A1 (en) 2012-11-19 2014-05-22 Pieris Ag Novel specific-binding polypeptides and uses thereof
DK2950786T3 (da) 2013-01-31 2020-02-17 Gilead Pharmasset Llc Kombinationsformulering af to antivirale forbindelser
WO2014140210A1 (en) 2013-03-14 2014-09-18 Pieris Ag Novel binding proteins for pcsk9
ES2792503T3 (es) 2013-08-27 2020-11-11 Gilead Pharmasset Llc Formulación combinada de dos compuestos antivirales
AU2015205530B8 (en) 2014-01-13 2019-09-19 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
CA2949405C (en) 2014-05-22 2023-08-01 Pieris Pharmaceuticals Gmbh Novel specific-binding polypeptides and uses thereof
CN107207574A (zh) 2015-01-28 2017-09-26 皮里斯制药有限公司 血管生成特异性的新型蛋白
EA035824B1 (ru) 2015-02-18 2020-08-17 Пайерис Фармасьютикалс Гмбх Новые белки, специфичные к пиовердину и пиохелину
WO2016177762A1 (en) 2015-05-04 2016-11-10 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
CN107636014B (zh) 2015-05-04 2021-12-07 皮里斯制药有限公司 抗癌融合多肽
CA2982034A1 (en) 2015-05-18 2016-11-24 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
HUE061108T2 (hu) 2015-05-18 2023-05-28 Pieris Pharmaceuticals Gmbh Rákellenes fúziós polipeptid
EP3115371A1 (en) 2015-07-07 2017-01-11 Sanofi Fusion molecules
CA2988831A1 (en) 2015-07-15 2017-01-19 Pieris Pharmaceuticals Gmbh Novel proteins specific for lag-3
CA3004918A1 (en) 2015-11-30 2017-06-08 Pieris Australia Pty Ltd. Novel anti-angiogenic fusion polypeptides
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
WO2018087108A1 (en) 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
EP3571219A1 (en) 2017-01-18 2019-11-27 Pieris Pharmaceuticals GmbH Lipocalin muteins with binding affinity for lag-3
HRP20230590T2 (hr) 2018-07-31 2024-02-16 Pieris Pharmaceuticals Gmbh Novi fuzijski protein specifičan za cd137 i pd-l1
CA3124441A1 (en) 2019-02-26 2020-09-03 Pieris Pharmaceuticals Gmbh Novel fusion proteins specific for cd137 and gpc3
CN116249709A (zh) 2020-06-05 2023-06-09 皮里斯制药有限公司 靶向4-1bb的多聚体免疫调节剂
MX2023011780A (es) 2021-04-08 2023-10-11 Pieris Pharmaceuticals Gmbh Nuevas muteinas de lipocalina especificas para factor de crecimiento de tejido conectivo (ctgf).
WO2022243341A1 (en) 2021-05-18 2022-11-24 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding affinity for ox40
WO2024064713A1 (en) 2022-09-21 2024-03-28 Seagen Inc. Novel fusion protein specific for cd137 and cd228

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4609546A (en) * 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4681848A (en) * 1982-09-22 1987-07-21 Takeda Chemical Industries, Ltd. Novel peptide and use thereof
GB8430252D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
DE3719046A1 (de) * 1987-06-06 1988-12-15 Basf Ag Verwendung von salzen von sulfonamidcarbonsaeuren als korrosionsinhibitoren in waessrigen systemen
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5238915A (en) * 1991-02-08 1993-08-24 Wakunaga Seiyaku K.K. Aromatic composition and method for controlling aroma
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5281698A (en) * 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
DK0730470T3 (da) * 1993-11-10 2002-06-03 Enzon Inc Forbedrede interferonpolymerkonjugater
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
JP2758154B2 (ja) * 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
US5695760A (en) * 1995-04-24 1997-12-09 Boehringer Inglehiem Pharmaceuticals, Inc. Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
CA2236591C (en) * 1995-11-02 2012-01-03 Schering Corporation Continuous low-dose cytokine infusion therapy
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
PL192364B1 (pl) * 1998-06-08 2006-10-31 Hoffmann La Roche Zastosowanie koniugatu PEG-IFN-α 2A w połączeniu z rybawiryną

Also Published As

Publication number Publication date
CL2010000828A1 (es) 2011-02-11
SI1087778T1 (sl) 2006-02-28
CA2334267A1 (en) 1999-12-16
NO325598B1 (no) 2008-06-23
JP3839667B2 (ja) 2006-11-01
AU767131B2 (en) 2003-10-30
ATE307597T1 (de) 2005-11-15
HUP0102033A3 (en) 2010-01-28
JP2002517451A (ja) 2002-06-18
IL139786A (en) 2007-10-31
ES2251196T3 (es) 2006-04-16
DE69927971T2 (de) 2006-07-27
PL344794A1 (en) 2001-11-19
DE69927971D1 (de) 2005-12-01
AU4503399A (en) 1999-12-30
ID29285A (id) 2001-08-16
MY124091A (en) 2006-06-30
EP1087778B1 (en) 2005-10-26
JP2006160759A (ja) 2006-06-22
NZ508249A (en) 2003-02-28
YU77000A (sh) 2003-08-29
HRP20000808A2 (en) 2001-10-31
CA2334267C (en) 2009-02-17
PL192364B1 (pl) 2006-10-31
HU228218B1 (en) 2013-02-28
EP1087778A1 (en) 2001-04-04
CO5050297A1 (es) 2001-06-27
HK1037981A1 (en) 2002-03-01
AR019855A1 (es) 2002-03-20
RU2271217C2 (ru) 2006-03-10
KR20010052622A (ko) 2001-06-25
IL139786A0 (en) 2002-02-10
CZ298681B6 (cs) 2007-12-19
US20070196385A1 (en) 2007-08-23
CZ20004487A3 (en) 2001-06-13
DK1087778T3 (da) 2005-12-19
US20030053986A1 (en) 2003-03-20
SA99200208B1 (ar) 2006-08-15
KR20050055053A (ko) 2005-06-10
TWI241913B (en) 2005-10-21
CN1170543C (zh) 2004-10-13
CN1305382A (zh) 2001-07-25
PE20000560A1 (es) 2000-07-05
US20050031589A1 (en) 2005-02-10
MA26641A1 (fr) 2004-12-20
HUP0102033A2 (hu) 2001-10-28
BR9911076A (pt) 2001-02-20
NO20006178D0 (no) 2000-12-05
WO1999064016A1 (en) 1999-12-16
ZA200006814B (en) 2002-05-03
TR200003635T2 (tr) 2001-04-20
RS50144B (sr) 2009-03-25

Similar Documents

Publication Publication Date Title
NO20006178D0 (no) Anvendelse av PEG-IFN-&lt;alfa&gt; og ribavirin for behandling av kronisk hepatitt C
BR9608758A (pt) Uso de ribavirina e interferom alfa para o tratamento de hepatite c
NO983147L (no) Anvendelse av en antagonist av PPAR-&lt;alfa&gt; og PPAR-&lt;gamma&gt; for behandling av syndrom X
NO991700D0 (no) Benzimidazol-2-karbamater for behandling av virusinfeksjoner og cancer
NO20005755L (no) Kombinasjonsterapi omfattende ribavirin og interferon-&lt;alfa&gt; hos antivirusbehandlingsnaive pasienter med kronisk hepatitt C- infeksjon
NO991151D0 (no) Forbindelse og anvendelse derav
DE60017241D1 (de) Unterwasserbehandlungsanordnung und -verfahren
EE05507B1 (et) Rosuvastatiini ZD4522) kasutamine heterosgootseperekondliku hperkolesteroleemia raviks
NO20003807D0 (no) &lt;alfa&gt;-ketoamidinhibitorer av 20S proteasome
DK1021410T3 (da) Prostaglandinagonister og deres anvendelse til behandling af knogletilstande
EE200100659A (et) Diaminotiasoolid ja nende kasutamine proteiinikinaaside pärssimiseks
DE69940166D1 (de) Feinteilige acrylpolymere und diese enthaltende plastisole
NO20004752L (no) Flerlags plastrør og bruk av samme
DK1176964T3 (da) Brug af ET743 til behandling af cancer
NO20022245L (no) Onkolyttiske kombinasjoner for behandling av cancer
NO995622L (no) Karbocyklisk nukleosidhemisulfat og anvendelse derav for behandling av virale infeksjoner
ATE259825T1 (de) Hemihydrat von 16.alpha.-bromoepiandrosterone
NO20010464D0 (no) Fremgangsmåter og sammensetninger for behandling av gastroösofrageal-reflukssyndrom
DE69930017D1 (de) Glaskeramischer körper
ZA988519B (en) Use of IFN-alpha and amantadine for the treatment of chronic hepatitis C
NO20013464D0 (no) Anvendelse av 3-isoksazolidinoner og hydroksylaminsyrer for behandling av infeksjoner
ID22249A (id) Aparatus damper yang dipakai pada saluran pembawa gas
ITMI20002171A0 (it) Corpo per alloggiarvi componenti e/o elettronici
KR980003137U (ko) 퇴수를 재공급 사용토록 한 개량부동전
NO20010470D0 (no) Koplingsinnretning og anvendelse av samme

Legal Events

Date Code Title Description
MK1K Patent expired